Denali Therapeutics Inc.

NASDAQ:DNLI

Biotechnology

Healthcare
$18.40 +0.40%

+$0.09 today

Market cap
$2.95B
Beta
1.01
P/E (TTM)
-8.7
EPS (TTM)
-$2.72
52W Low $12.58High $24.65

Volume 2.37M

Average 1.84M

DNLI Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Denali Therapeutics Inc.NASDAQ: DNLI

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin at 97.4%

Gross margin was 97.4% in Q2 FY2026. On a trailing-twelve-month basis it was -61.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
97.4%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMJun 2026
-61.0%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2023
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How DNLI compares with its peers on the latest reported figures

  • DNLI's LTM Jun 2026 gross margin of -61.0% is the 4th highest of the 5 companies compared; the peer median is 96.4%.
DNLI Competitors Peer median
Gross Margin for DNLI and competitors
Company Period LTM level YoY 3-year change
IONSIonis Pharmaceuticals, Inc.LTM Sep 202698.2% -0.6 pp+0.7 pp
NBIXNeurocrine Biosciences, Inc.LTM Sep 202697.8% -0.6 pp-0.3 pp
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202695.0% ——
DNLIDenali Therapeutics Inc.LTM Jun 2026-61.0% ——
ALECAlector, Inc.LTM Mar 2026-61.2% -68.0 pp-45.9 pp
PRAXPraxis Precision Medicines, Inc.FY2025— ——
AMLXAmylyx Pharmaceuticals, Inc.FY2025— ——
BHVNBiohaven Ltd.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
PMNProMIS Neurosciences, Inc.FY2025— ——
Peer median (excluding DNLI) 96.4%-0.6 pp-0.3 pp

Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.66M108.46M330.53M00
Cost of Revenue000011.18M
Gross Profit48.66M108.46M330.53M0(11.18M)
Gross Margin100.0%100.0%100.0%——
Research & Development265.35M358.73M423.88M396.44M418.78M
Selling, General & Admin79.06M90.48M103.35M105.44M97.1M
Operating Expenses344.41M449.21M527.23M487.34M544.16M
Depreciation & Amortization8.59M10.38M16.73M8.99M14.81M
EBITDA(282.56M)(315.59M)(128.47M)(492.89M)(497.63M)
EBITDA Margin-580.7%-291.0%-38.9%——
Operating Income(295.75M)(340.74M)(196.7M)(487.34M)(555.34M)
Operating Margin-607.8%-314.2%-59.5%——
Interest Income4.6M14.77M51.51M64.64M42.9M
Interest Expense00000
Other Income / Expenses4.6M14.77M51.51M64.64M42.9M
Income Before Tax(291.16M)(325.97M)(145.19M)(422.71M)(512.44M)
Pre-Tax Margin-598.3%-300.5%-43.9%——
Income Tax Expense(575K)21K30K68K102K
Net Income(290.58M)(325.99M)(145.22M)(422.77M)(512.54M)
Net Margin-597.2%-300.6%-43.9%——
EPS (Basic)(2.39)(2.60)(1.06)(2.57)(2.97)
EPS (Diluted)(2.39)(2.60)(1.06)(2.57)(2.97)
Weighted Avg Shares121.52M125.53M137.37M164.47M175.46M
Weighted Avg Shares (Diluted)121.52M125.53M137.37M164.47M175.46M

Denali Therapeutics Inc.

NASDAQ:DNLI

Intrinsic Alpha fair value

Locked

Current Price

$18.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.